Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Specify a stock or a cryptocurrency in the search bar to get a summary
Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Medicenna Therapeutics Corp
MDNAFCurrent price
1.27 USD
-0.23 USD (-15.28%)
Last closed
1.76 CAD
Company
www.medicenna.com
ISIN
CA58490H1073
Sector
Healthcare
Industry
Biotechnology
Exchange
TO
Capitalization
190 723 940 CAD
Yield for 12 month
+233.33 %
1Y
3Y
5Y
10Y
15Y
MDNAF
Medicenna Therapeutics Corp., an immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer and other diseases. It develops bizaxofusp (MDNA55), an interleukin- 4 (IL-4) EC for the treatment of recurrent glioblastoma, as well as for brain tumors. The company also develops MDNA11, an enhanced version of IL-2 to activate and proliferate the immune cells needed to fight cancer; MDNA209, an IL-2 antagonist for autoimmune diseases, such as multiple sclerosis and graft versus host disease; MDNA413, a dual IL-4/IL-13 antagonist to treat cancer immunotherapies; MDNA113, a masked bi-functional anti-PD1-IL2 Superkine for various solid tumors; and MDNA132, an IL-13 Superkine for various tumors. In addition, it provides BiSKITs platform to develop designer Superkines by fusing them to other proteins, inhibitors, antibodies, cytokines, or other Superkines Medicenna Therapeutics Corp. is headquartered in Toronto, Canada. Address: 2 Bloor Street West, Toronto, ON, Canada, M4W 3E2
Check your investment idea
Find the best to beat the market
TSLA
Tesla Motors
AAPL
Apple
MSFT
Microsoft
Analytics
WallStreet Target Price
6.06 CADP/E ratio
–Dividend Yield
–Current Year
–
Last Year
–
Current Quarter
+5 051 CAD
Last Quarter
–
Current Year
-5 051 CAD
Last Year
-5 051 CAD
Current Quarter
–
Last Quarter
-1 010 CAD
Key Figures MDNAF
1 year
3 years
5 years
10 years
EBITDA
-18 434 017 CAD
Operating Margin TTM
PE Ratio
–
Return On Assets TTM
-32.8 %
PEG Ratio
–
Return On Equity TTM
-105.43 %
Wall Street Target Price
6.06 CAD
Revenue TTM
–
Book Value
0.3 CAD
Revenue Per Share TTM
Dividend Share
–
Quarterly Revenue Growth YOY
–
Dividend Yield
–
Gross Profit TTM
–
Earnings per share
-0.34 CAD
Diluted Eps TTM
-0.34 CAD
Most Recent Quarter
II 2024
Quarterly Earnings Growth YOY
–
Profit Margin
–
Dividend Analytics MDNAF
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History MDNAF
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
–
Ex Dividend Date
–
Forward Annual Dividend Yield
–
Last Split Factor
1:14
Payout Ratio
–
Last Split Date
03.03.2017
Dividend Date
03.03.2017
Stock Valuation MDNAF
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
–
Forward PE
204.0816
Enterprise Value Revenue
–
Price Sales TTM
–
Enterprise Value EBITDA
-6.1093
Price Book MRQ
7.4158
Financials MDNAF
1 year
3 years
5 years
10 years
15 years
| Results | 2019 | Dynamics |
* The data for this period has not yet been published
Technical indicators MDNAF
For 52 weeks
0.38 CAD
3.01 CAD
50 Day MA
2.21 CAD
Shares Short Prior Month
51 116
200 Day MA
1.91 CAD
Short Ratio
0.55
Shares Short
33 709
Short Percent
0.15 %
BeatStart